Navigation Links
Rat Frozen Mixed Tissue Microarray, Panel- 2 from Zyagen Laboratories

ProductsRat Frozen Mixed Tissue Microarray, Panel- 2 from Zyagen Laboratories
Company Zyagen Laboratories
Item Rat Frozen Mixed Tissue Microarray, Panel- 2
Price $310.00
Description Zyagen tissue microarrays are derived from frozen embedded tissue blocks, which are subjected to rigorous quality control procedures to ensure the highest quality. Tissues of each array are manually assembled in one block, sectioned at a thickness of 7 microns and mounted on coated slides. Sections are large (3-5 mm in diameter) in comparison to core sections made using Tissue Arrayer. Arrays enable high throughput screening of large number of tissue specimens by immunohistochemistry and in situ hybridization.

Tissues: Kidney, Lung, Heart, Testis, Ovary, Pancreas, Liver, Spleen, Stomach, Jejunum, skeletal muscles
Info Zyagen LaboratoriesZyagen Laboratories
10225 Barnes Canyon Road
San Diego, CA 92121
Customer Service: 858-442-0704
Fax Number: 858-546-0736
Web Site: http://www.zyagen.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Frozen-EZ Yeast Transformation II Kit from Zymo Research
2. Mouse Frozen Reproductive Tissue Microarray from Zyagen Laboratories
3. Mouse Frozen Mixed Tissue Microarray, Panel -3 from Zyagen Laboratories
4. Mouse Frozen Neuronal Tissue Microarray from Zyagen Laboratories
5. Mouse Frozen Digestive Tissue Microarray from Zyagen Laboratories
6. Rat Frozen Reproductive Tissue Microarray from Zyagen Laboratories
7. Rat Frozen Neuronal Tissue Microarray from Zyagen Laboratories
8. Sf9 Frozen Cells (Graces Media) from Invitrogen
9. Sf21 Frozen Cells (Graces Media) from Invitrogen
10. Frozen Tissue Section Panel - Monkey (Cynomolgus) Normal Tissue, Multi-tissue I from BioChain
11. Frozen Tissue Section Panel - Monkey (Rhesus) Normal Tissue, Multi-tissue I from BioChain
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... , March 31, 2015   Guidepoint , ... launch of the Post-Surgical Pain Management TRACKER, part of ... tracking usage trends in the medical device and therapeutics ... to data including treatment volumes, market share, and adoption ... pain associated with joint surgery. The Post-Surgical ...
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... Organization (EMBO) and the Federation of European Biochemical ... Friedrich Miescher Institute for Biomedical Research in Basel, ... Women in Science Award. Professor Gasser has been ... stability and epigenetics and her commitment to mentoring ...
... (New York, NY) The Alfred P. Sloan ... outstanding U.S. and Canadian researchers as recipients of Sloan ... fellowships are given to early-career scientists and scholars whose ... next generation of scientific leaders. "Today,s Sloan Research ...
... DETROIT Technology to restore vision through the use ... a Wayne State University professor and scientific director of ... Eye Institute has attracted additional funding for therapy ... grant from their affiliate, National Neurovision Research Institute, to ...
Cached Biology News:Susan M. Gasser to receive the 2012 FEBS/EMBO Women in Science Award 2Sloan Research Fellowships awarded to 126 young scholars 2Wayne State-licensed technology receives grant from the Foundation Fighting Blindness 2
(Date:4/16/2015)... San Francisco, CA (PRWEB) April 16, 2015 ... is scheduled to report first quarter results on Thursday, ... the announcement, Cytokinetics’ senior management will host a conference ... and financial results and the company’s outlook for the ... and can be accessed from the homepage and in ...
(Date:4/16/2015)... 16, 2015 According to the ... an outside source was ranked first among the ... related to lifting, pushing, pulling, holding, carrying, or ... costs. The David Round Company takes statistics like ... working hard to develop and design equipment that ...
(Date:4/16/2015)... 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... joint venture with G-treeBNT (ReGenTree LLC) has retained ... trial for the orphan disorder, neurotrophic keratopathy (NK), ... eye syndrome (DES) in the U.S.  Both trials ... this year.  Each of these eye disorders was ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3